A phase II study presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium showed that CTX-009 combined with paclitaxel administered as second- or third-line therapy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback